Use this guide to educate beneficiaries about the program and how they could benefit
Cell Metab (2009) 10(2):99109.10.1016/j.cmet.2009.07.005 107 BeglingerCDegenLMatzingerDDAmatoMDreweJ
Am J Physiol Endocrinol Metab (2011) 301(2):E31725.10.1152/ajpendo.00077.2011 133 FengRQianCLiuQJinYLiuLLiSet alExpression of sweet taste receptor and gut hormone secretion in modelled type 2 diabetes
Lillys Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Most insurance plans cover GLP-1s when they are used to treat diabetes, so those patients can usually avoid the roughly $1,000 monthly price tag of the medications
The New England Journal of Medicine , 384(11), 9891002